Benzodiazepine use in older adults enrolled in a health maintenance organization

American Journal of Geriatric Psychiatry

Volumn 11, Issue 5, 2003, Pages 568-576

  Gray, Shelly L ^a   Eggen, Anne Elise ^b   Blough, David ^a   Buchner, Dave ^a   LaCroix, Andrea Z ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; FLURAZEPAM; LORAZEPAM; TEMAZEPAM; TRIAZOLAM;

ACADEMIC ACHIEVEMENT; AGED; ARTICLE; BODY MASS; CHRONIC DISEASE; COGNITIVE DEFECT; DATA ANALYSIS; DEMOGRAPHY; DEPRESSION; DRUG USE; FALLING; FEMALE; GERONTOPSYCHIATRY; HEALTH BEHAVIOR; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROMOTION; HEALTH STATUS; HIP FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROLOGIC DISEASE; PAIN; PHARMACY; QUESTIONNAIRE; SEX DIFFERENCE; SIDE EFFECT; STRESS;

EID: 0041971009     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200309000-00012     Document Type: Article

References (31)

1. Folks DG, Burke WJ: Psychotherapeutic agents in older adults: sedative-hypnotics and sleep. Clin Geriatr Med 1998; 14:67-86
2. Isacson D: Long-term benzodiazepine use: factors of importance and the development of individual use patterns over time: a 13-year follow-up in a Swedish community. Soc Sci Med 1997; 44:1871-1880
3. Simon GE, VonKorff M, Barlow W, et al: Predictors of chronic benzodiazepine use in a health maintenance organization sample. J Clin Epidemiol 1996; 49:1067-1073
4. Egan M, Moride Y, Wolfson C, et al: Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence, and risk factors. J Am Geriatr Soc 2000; 48:811-816
5. Blazer D, Hybels C, Simonsick E, et al: Sedative, hypnotic, and antianxiety medication use in an aging cohort over ten years: a racial comparison. J Am Geriatr Soc 2000; 48:1073-1079
6. Gleason PP, Schulz R, Smith NL, et al: Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med 1998; 13:243-250
7. Taylor S, McCracken CF, Wilson KC, et al: Extent and appropriateness of benzodiazepine use results from an elderly urban community. Br J Psychiatry. 1998; 173:433-438
8. Mayer-Oakes SA, Kelman G, Beers MH, et al: Benzodiazepine use in older, community-dwelling southern Californians: prevalence and clinical correlates. Ann Pharmacother 1993; 27:416-421
9. van Hulten R, Leufkens HG, Bakker A: Usage patterns of benzodiazepines in a Dutch community: a 10-year follow-up. Pharm World Sci 1998; 20:78-82
10. Jorm AF, Grayson D, Creasey H, et al: Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health 2000; 24:7-10
11. Wagner EH, LaCroix AZ, Grothaus L, et al: Preventing disability and falls in older adults: a population-based randomized trial. Am J Public Health 1994; 84:1800-1806
12. Wagner EH, Grothaus L, Hecht JA, et al: Factors associated with participation in a senior health-promotion program. Gerontologist 1991; 31:598-602
13. Saunders KW, Stergachis A, VonKorff M: Group Health Cooperative of Puget Sound, in Pharmacoepidemiology. Edited by Strom BL. London, UK, Wiley, 1994
14. Kastrup EK (ed): Facts and comparisons, 2000, in Facts and Comparisons; 2000. Edited by Kastrup EK. St. Louis, MO, 2000
15. McEvoy GK (ed): AHFS Drug Information, 2000. Edited by McEvoy GK. Bethesda, MD, American Society for Healthcare Pharmacists; 2000
16. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report: National Institutes of Health. Obes Res 1998;6(suppl2):51S-209S
17. Veit CT, Ware JE: The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1985; 51:730-742
18. Scholes D, LaCroix AZ, Wagner EH, et al: Tracking progress toward national health objectives in the elderly: what do restricted activity days signify? Am J Public Health 1991; 81:485-488
19. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45:197-203
20. Little RJA, Rubin DB: Statistical Analysis with Missing Data. New York, Wiley; 1987
21. Statistical Solutions System for Data Analysis, v. 2.0. Saugus, MA, Statistical Solutions; 1999
22. Rojas-Fernandez CH, Carver D, Tonks R: Population trends in the prevalence of benzodiazepine use in the older population of Nova Scotia: a cause for concern? Can J Clin Pharmacol 1999; 6:149-156
23. Von Korff M, Simon G: The relationship between pain and depression. Br J Psychiatry 1996;(168suppl):101-108
24. National Task Force on the Prevention and Treatment of Obesity: Overweight, obesity, and health risk. Arch Intern Med 2000; 160:898-904
25. Rosmond R, Bjorntorp P: Psychiatric ill-health of women and its relationship to obesity and body fat distribution. Obes Res 1998; 6:338-345
26. Rosmond R, Lapidus L, Marin P, et al: Mental distress, obesity, and body fat distribution in middle-aged men. Obes Res 1996; 4:245-252
27. Ensrud KE, Lipschutz RC, Cauley JA, et al: Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 1997; 103:274-280
28. Farmer ME, Harris T, Madans JH, et al: Anthropometric indicators and hip fracture: The NHANES I Epidemiologic Follow-Up Study. J Am Geriatr Soc 1989; 37:9-16
29. Ray WA, Griffin MR, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262:3303-3307
30. Herings RM, Stricker BH, de Boer A, et al: Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155:1801-1807
31. Ronning M, Blix HS, Harbo BT, et al: Different versions of the anatomical therapeutic chemical classification system and the defined daily dose: are drug utilisation data comparable? Eur J Clin Pharmacol 2000; 56:723-727